Related Experiment Video
Updated: Mar 26, 2026
12:27
A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors
Published on: June 8, 2022
4.0K
Sphingosine 1-phosphate signaling in astrocytes: Implications for progressive multiple sclerosis
Mauricio F Farez1, Jorge Correale1
1Department of Neurology, Raúl Carrea Institute for Neurological Research (FLENI), Buenos Aires, Argentina.
Journal of the Neurological Sciences
|January 27, 2016
Summary
Primary Progressive Multiple Sclerosis (PPMS) lacks effective treatments. Targeting the sphingosine 1-phosphate pathway in astrocytes shows promise for developing new therapies for this debilitating neurological disorder.
Area of Science:
- Neuroimmunology
- Cellular Neuroscience
Background:
- Multiple sclerosis (MS) is an autoimmune disorder affecting the central nervous system.
- Primary Progressive Multiple Sclerosis (PPMS) is a severe form lacking effective therapies.
- Astrocytes, a type of glial cell, are implicated in MS disease progression.
Purpose of the Study:
- To explore the potential of targeting the sphingosine 1-phosphate (S1P) pathway in astrocytes for PPMS treatment.
- To investigate S1P receptor expression on astrocytes and its role in disease.
Main Methods:
- Review of existing literature on MS, PPMS, astrocytes, and the S1P pathway.
- Analysis of S1P receptor expression in glial cells.
- Examination of preclinical data from animal models of MS.
Main Results:
- Sphingosine 1-phosphate receptors are expressed on astrocytes.
- Modulating the S1P pathway has shown benefits in animal models of MS.
- Fingolimod, an S1P modulator, is used for relapsing-remitting MS.
Conclusions:
- The S1P pathway in astrocytes represents a promising therapeutic target for PPMS.
- Further research into S1P modulation could lead to novel treatments for progressive forms of MS.
